Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [1] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Roth, K.
    Wang, Y.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 808 - 813
  • [2] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
    Aggarwal, Rahul
    Bryce, Alan
    Ryan, Charles J.
    Harzstark, Andrea
    Derleth, Christina
    Kim, Won
    Friedlander, Terence
    Lin, Amy M.
    Rodvelt-Bagchi, Tammy
    Dhawan, Mallika
    Zhang, Li
    Lee, Mina
    Siebeneck, Eric
    Hough, Jeffrey
    Small, Eric J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04)
  • [3] A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
    Sridhar, Srikala S.
    Canil, Christina M.
    Chi, Kim N.
    Hotte, Sebastien J.
    Ernst, Scott
    Wang, Lisa
    Chen, Eric X.
    Juhasz, Agnes
    Yen, Yun
    Murray, Peter
    Zwiebel, James A.
    Moore, Malcolm J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 927 - 933
  • [4] A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
    Srikala S. Sridhar
    Christina M. Canil
    Kim N. Chi
    Sebastien J. Hotte
    Scott Ernst
    Lisa Wang
    Eric X. Chen
    Agnes Juhasz
    Yun Yen
    Peter Murray
    James A. Zwiebel
    Malcolm J. Moore
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 927 - 933
  • [5] The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
    Mahammedi, Hakim
    Planchat, Eloise
    Pouget, Melanie
    Durando, Xavier
    Cure, Herve
    Guy, Laurent
    Van-Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Bayet-Robert, Mathilde
    Gadea, Emilie
    Abrial, Catherine
    Thivat, Emilie
    Chollet, Philippe
    Eymard, Jean-Christophe
    ONCOLOGY, 2016, 90 (02) : 69 - 78
  • [6] Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer
    Passildas-Jahanmohan, Judith
    Eymard, Jean-Christophe
    Pouget, Melanie
    Kwiatkowski, Fabrice
    Van Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Durando, Xavier
    Abrial, Catherine
    Richard, Damien
    Ginzac Couve, Angeline
    Thivat, Emilie
    Monange, Brigitte
    Chollet, Philippe
    Mahammedi, Hakim
    CANCER MEDICINE, 2021, 10 (07): : 2332 - 2340
  • [7] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
  • [8] Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
    Hussain, A.
    DiPaola, R. S.
    Baron, A. D.
    Higano, C. S.
    Tchekmedyian, N. S.
    Johri, A. R.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 492 - 497
  • [9] A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Morris, Michael J.
    Kelly, W. Kevin
    Slovin, Susan
    Ryan, Charles
    Eicher, Caitlin
    Heller, Glenn
    Scher, Howard I.
    JOURNAL OF UROLOGY, 2007, 178 (06) : 2378 - 2383
  • [10] Docetaxel Plus Oral Metronomic Cyclophosphamide: A Phase II Study With Pharmacodynamic and Pharmacogenetic Analyses in Castration-Resistant Prostate Cancer Patients
    Derosa, Lisa
    Galli, Luca
    Orlandi, Paola
    Fioravanti, Anna
    Di Desidero, Teresa
    Fontana, Andrea
    Antonuzzo, Andrea
    Biasco, Elisa
    Farnesi, Azzurra
    Marconcini, Riccardo
    Francia, Giulio
    Danesi, Romano
    Falcone, Alfredo
    Bocci, Guido
    CANCER, 2014, 120 (24) : 3923 - 3931
12345